References
- 1. Valent P., Horny H-P, Li CY, Longley J.B., Metcalfe D.D., Parwaresch R.M., et al. Mastocytosis (mast cell disease). In: World Health Organization (WHO) Classification of Tumours. Pathology & Genetics. Tumoursof Haematopoietic and Lymphoid Tissues. Eds: Jaffe ES, Harris NL, Stein H, Vardiman JW. IARC PressLyon, France, 2001, pp291-302.
- 2. Peter Valent, Cem Akin, Karin Hartmann, Gunnar Nilsson, Andreas Reiter et al. Advances in the Classification and Treatment of Mastocytosis Current Status and Outlook toward the Future, Cancer Res; 77(6) March 15, 2017.
- 3. Butov J.S., Skripkin J.K., Ivanova O.L. Dermatovenereology. National guidance. Brief publication - М.: GEHOTAR-Media, 2013. - 896 pp.
- 4. Arber D.A., Orazi A., Hasserjian R. et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016; 127 (20): 2391-405.
- 5. Peter Valent. Diagnosis and management of mastocytosis: an emerging challenge in applied hematology Hematology 2015.
- 6. Horny HP, Akin C, Metcalfe DD, Escribano L, Bennett JM, Valent P, et al. Mastocytosis (mast cell disease). In: Eds: Swerdlow S.H., Campo E., Harris N.L., Jaffe E.S., Pileri S.A., Stein H., et al. editors. WorldHealthOrganization (WHO) Classification of Tumours. Pathology & Genetics. Tumours of Haematopoietic and Lymphoid Tissues. Lyon, France: IARC Press; 2008. pp 54-63.
- 7. ValentP, AkinC, SperrWR, HornyHP,ArockM, LechnerK, et al. Diagnosis and treatment of systemic mastocytosis: state of the art. Br J Haematol. 2003; 122: 695-717.
- 8. Wöhrl S, Moritz KB, Bracher A et al. A c-kit mutation in exon 18 in familial mastocytosis. J Invest Dermatol. 2013; 133 (3): 839-41.
- 9. Nicola Wagner, Petra Staubach Mastocytosis – pathogenesis, clinical manifestation and treatment, 2018 Deutsche Dermatologische Gesellschaft (DDG). Published by John Wiley & Sons Ltd. | JDDG
- 10. Valent P, Escribano L, Broesby-Olsen S et al. European Competence Network on Mastocytosis. Proposed diagnostic algorithm for patients with suspected mastocytosis: a proposal of the European Competence Network on Mastocytosis. Allergy 2014.
- 11. Tefferi, A. & Pardanani, A. Systemic mastocytosis: current concepts and treatment advances. Current Hematology Reports. 2004; 3: 197-202.
- 12. Nagornaya N.V., Bordyugova Ye.V., Koval A.P., Dubovaya A.V. Mastocytosis in Children: Literature Review and Own Clinical Observation. Zdorov’e rebenka. 2013. № 7 (50). Р. 173-177.
- 13. Batkaev E.A., Olenich I.V., Chistyakova I.A., Avedikian S.S., Matheopoulos R.G., Malyarenko E.N., Bobrov A.M. Mastocytosis, diagnosis and treatment. Vestnik poslediplomnogo medicinskogo obrazovaniya. 2016. № 1. С. 11-16.
- 14. Melikian A.L., Subortseva I.N., Goriacheva S.R., Kolosheĭnova T.I., Vakhrusheva M.V., Kovrigina A.M., Sudarikov A.B., Dvirnyk V.N., Obukhova T.N. Mastocytosis. Review of the literature and description of clinical cases. Terapevticheskij arhiv. 2014. Т. 86. № 12. Р. 127-134.
- 15. Proshutinskaya D.V., Makoveckaya O.S. Clinical features of mastocytosis at pediatric patients. Vestnik dermatologii i venerologii. 2017. № 1.Р. 12-20.
- 16. Robyn M. Scherber and Uma Borate How we diagnose and treat systemic mastocytosis in adults. 2017 John Wiley & Sons Ltd, British Journal of Haematology
- 17. Valent P, Akin C, Arock M, et al. Definitions, criteria and global classification of mast cell disorders with special reference to mast cell activation syndromes: a consensus proposal. Int Arch Allergy Immunol. 2012; 157:215-225.
- 18. Krivolapov J.A. Bone marrow biopsy: research and practice publication. Practical medicine. 2014. -528 с. ISBN: 978-5-98811-308-9
- 19. Zhang LY, Smith ML, Schultheis B, Fitzgibbon J, Lister TA, Melo JV, et al. A novel K509I mutation of KIT identified in familial mastocytosis-in vitro and in vivo responsiveness to imatinib therapy. Leuk Res 2006; 30:373–8.
- 20. Bai CG, Hou XW, Wang F, Qiu C, Zhu Y, Huang L, Zhao J, Xu JJ, Ma DL (2012) Stem cell factor-mediated wild-type KIT receptor activation is critical for gastrointestinal stromal tumor cell growth. World J Gastroenterol 18(23):2929–2937. doi:10.3748/wjg.v18. i23.2929
- 21. Peter ValentMastocytosis: a paradigmatic example of a rare disease with complex biology and pathology Am J Cancer Res 2013; 3(2):159-172
- 22. H.-P. Horny, K. Sotlar, P. Valent Evaluation of Mast Cell Activation Syndromes: Impact of Pathology and ImmunohistologyInt Arch Allergy Immunol 2012; 159:1–5
- 23. Jensen RT. Gastrointestinal abnormalities and involvement in systemic mastocytosis. Hematol Oncol Clin North Am 2000; 14:579–623.
- 24. Horny HP, Sotlar K, Valent P. Mastocytosis: state ofthe art. Pathobiology 2007; 74:121–32.
- 25. Wimazal F, Sperr WR, Horny H-P, Carroll V, Binder BR, Fonatsch C, Walchshofer S, Fo¨dinger M, Schwarzinger I, Samorapoompichit P, Chott A, Dvorak AM, Lechner K, Valent P. Hyperfibrinolysis in a case of myelodysplastic syndrome with leukemic spread of mast cells. Am J Hematol 1999; 61:66–76.
- 26. Khantawatana S, Carias R, Arnaout R, Hu J, Irani AM, Schwartz LB. The potential clinical utility of serum alpha-protryptase levels. J Allergy Clin Immunol 1999; 103:1092–9.
- 27. Lennartsson J, Ronnstrand L (2012) Stem cell factor receptor/ cKit: from basic science to clinical implications. Physiol Rev 92(4): 1619–1649. doi:10.1152/physrev.00046.2011
- 28. Tsibulkina V.N., Tsibiakin N.A. Pathophysiology of mast cells in mastocytosis: implications for clinics and diagnosis. Prakticheskaya medicina. 2016. № 9 (101). Р. 7-11.
- 29. Cardet JC, Akin C, Lee MJ (2013) Mastocytosis: update on pharmacotherapy and future directions. Expert Opin Pharmacother 14(15):2033–2045. doi:10.1517/14656566.2013.824424
- 30. Akin C, Kirschenbaum AS, Semere T, Worobec AS, Scott LM, Metcalfe DD. Analysis of the surface expression of c-kit and occurrence of the c-kit Asp816Val activating mutation in T cells, B cells, and myelomonocytic cells in patients with mastocytosis. ExpHematol 2000; 28: 140–7.
- 31. Andres C. Garcia-Montero, Maria Jara-Acevedo, Cristina Teodosio KIT mutation in mast cells and other bone marrow hematopoietic cell lineages in systemic mast cell disorders: a prospective study of the Spanish Network on Mastocytosis (REMA) in a series of 113 patients The American Society of Hematology 2006
- 32. Bodemer C, Hermine O, Palmerini F, Yang Y, Grandpeix-Guyodo C, Leventhal PS, et al. Pediatric mastocytosis is a clonal disease associated with D816V and other activating c-KIT mutations. J Invest Dermatol 2010; 130:804–15.
- 33. Daniel Elieh, Ali Komi, Todd Rambasek, Stefan Wöhrl Mastocytosis: from a Molecular Point of View Clinic Rev Allerg Immunol 2017
- 34. Longley BJ, Metcalfe DD. A proposed classification of mastocytosis incorporating molecular genetics. Hematol Oncol Clin North Am 2000; 14:697–701.
- 35. Giovanna De Matteisa, Roberta Zanott The impact of sensitive KIT D816V detection on recognition of Indolent Systemic Mastocytosis Leukemia Research 39 (2015) 273–278
- 36. Alvarez-Twose I, Jara-Acevedo M, Morgado JM, García-Montero A, Sanchez-Mu~noz L, Teodosio C, et al. Clinical, immunophenotypic, and molecular characteristics of well-differentiated systemic mastocytosis. J Allergy Clin Immunol 2016; 137:168–78
- 37. Georg Greiner, Michael Gurbisz Digital PCR: A Sensitive and Precise Method for KIT D816V Quantification in Mastocytosis Clinical Chemistry 64:3 (2018)
- 38. Akin C, Kirschenbaum AS, Semere T, Worobec AS, Scott LM, Metcalfe DD. Analysis of the surface expression of c-kit and occurrence of the c-kit Asp816Val activating mutation in T cells, B cells, and myelomonocytic cells in patients with mastocytosis. Exp Hematol 2000; 28:140–7.
- 39. Sperr WR, Horny H-P, Lechner K, Valent P. Clinical and biologic diversity of leukemias occuring in patients with mastocytosis. Leuk Lymphoma 2000; 37:473–86.
- 40. Metcalfe DD. The treatment of mastocytosis. J Invest Dermatol 1991; 96:55S–6S.
- 41. Marone G, Spadaro G, Granata F, Triggiani M. Treatment of mastocytosis: pharmacologic basis and current concepts, Leuk Res, this issue.
- 42. Turk J, Oates JA, Roberts LJ. Intervention with epinephrine in hypotension associated with mastocytosis. J Allergy Clin Immunol 1983; 71:189–92.
- 43. Graves L, Stechschulte DJ, Morris DC, Lukert BP. Inhibition of mediator release in systemic mastocytosis is associated with reversal of bone changes. J Bone Mineral Res 1994; 5: 1113–9.
- 44. Povoa P, Ducla-Soares J, Fernandes A, Palma-Carlos AG. A case of systemic mastocytosis; therapeutic efficacy of ketotifen. J Intern Med 1991; 229:475–7.
- 45. Horan RF, Scheffer AL, Austen KF. Cromolyn sodium in the management of systemic mastocytosis. J Allergy Clin Immunol 1990; 85:852–5.